Skip to Content

Tybost Approval History

  • FDA approved: Yes (First approved September 24th, 2014)
  • Brand name: Tybost
  • Generic name: cobicistat
  • Dosage form: Tablets
  • Company: Gilead Sciences, Inc.
  • Treatment for: HIV Infection

Tybost (cobicistat) is a potent inhibitor of cytochrome P450 3A (CYP3A) which acts as a pharmacoenhancing or "boosting" agent for antiviral drugs used in the treatment of HIV infection.

Development History and FDA Approval Process for Tybost

Sep 25, 2014Approval FDA Approves Tybost (cobicistat) for use in the treatment of HIV-1 Infection
Apr 21, 2014Gilead Sciences’ New Drug Application for Cobicistat for HIV Therapy Accepted by U.S. FDA
Apr 29, 2013Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat
Jun 29, 2012Gilead Submits New Drug Application to U.S. FDA for Boosting Agent Cobicistat

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.